NDAINJECTIONINJECTABLEPriority Review
Approved
Feb 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
FERRLECIT (sodium ferric gluconate complex) by Sanofi. Approved for parenteral iron replacement [epc]. First approved in 1999.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FERRLECIT is a parenteral iron replacement therapy administered by injection for patients unable to take oral iron supplements or requiring rapid iron repletion. It delivers iron via a sodium ferric gluconate complex to treat iron deficiency anemia in chronic kidney disease patients, particularly those on dialysis. The drug works by providing bioavailable iron that is incorporated into hemoglobin and stored in body iron pools.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential headcount contraction on the brand team in coming years.
Mechanism of Action
Pharmacologic Class:
Parenteral Iron Replacement
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.
Started Dec 2003
112 enrolled
Anemia
Career Relevance
FERRLECIT offers limited career growth opportunities due to its LOE-approaching status and mature market position with no active clinical development. Roles on this product are best suited for professionals seeking stable, established franchise management rather than innovation or launch experience.
Brand Manager
Worked on FERRLECIT at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.